Plain-English translation of NCT06839144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether propranolol and etodolac—two medications that work through different pathways in your body—can help prevent ovarian cancer from returning or spreading after surgery. You would take these medications starting five days before your planned ovarian cancer surgery, continue through the surgery day, and keep taking them afterward. Researchers want to see if this treatment approach is safe, well-tolerated, and whether it can reduce the chances of cancer recurrence.
Surgery is a key treatment for ovarian cancer, but unfortunately cancer often comes back after surgery. This trial is exploring whether this medication combination, given around the time of surgery, might protect against cancer progression by targeting specific biological signals that cancer cells rely on.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to receive either the active medications or a placebo. You'll start taking your assigned treatment five days before your planned ovarian cancer surgery and continue it for a period after surgery. The study will monitor your safety, how well you tolerate the medication, and will collect blood and tumor samples to understand how the treatment affects your cancer at a biological level. The research team will follow your health for three years to track whether the cancer returns.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Israel